MEDICAL and SCIENTIFIC ADVISORY BOARD
Dean Lee, M.D., Ph.D. Vice President, Medical Director, Cofounder, and Chair of SAB
His method has been implemented in at least seven first-in-human clinical trials of NK cell adoptive immunotherapy under FDA Investigational New Drug applications. Dr. Lee brings his vast knowledge of immunology, NK cell biology, GMP cell manufacturing, and clinical trials of adoptive cell therapy to CytoSen. As medical director, he leads clinical development of the company’s NK cell therapies toward approval.
Dr. Lee has also developed genetic and non-genetic methods for improving tumor targeting and tissue homing of NK cells, leading to over a dozen invention disclosures, patents, and commercial licensing agreements.
In 2016, Dr. Lee joined Nationwide Children’s Hospital and The Ohio State University School of Medicine as professor of Pediatrics and director of the new joint Cellular Therapy and Cancer Immunotherapy Program. He serves as co-chair of the Cellular Therapy Working Group for the Pediatric Blood and Marrow Transplant Consortium, and is a member of the Cellular Therapy Steering Committee of the Children’s Oncology Group, the NIH Recombinant DNA Advisory Committee, and the NIH Gene Transfer Safety Assessment Board. Dr. Lee achieved his B.A. in Natural Sciences at Fresno Pacific College, his M.D. at Loma Linda University, and his Ph.D. in immunology at Loma Linda University.
[–][+] Relevant publications
Stefan O. Ciurea, M.D.
Co-Founder and Medical Advisory Board Member
Dr. Ciurea received his MD degree from University of Medicine, Iasi, Romania, completed clinical training in Internal Medicine at Harrisburg Hospital/Penn State University where he was Chief Resident, Hematology/Oncology fellowship at University of Illinois at Chicago, and Hematopoietic Stem Cell Transplantation fellowship at MD Anderson Cancer. He became a faculty member in the Department of Stem Cell Transplantation and Cellular Therapy and was promoted to Associate Professor in 2014. He is the leader of the Haploidentical Stem cell Transplant Program at this institution.
[–][+] Relevant publications
Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 2017. Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO.
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 2017. Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, Solomon S, Nademanee A, Brown S, Slade M, Perez R, Rondon G, Forman SJ, Champlin RE, Kebriaei P, Ciurea SO.
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 2016. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO.
Haploidentical Donors: Can Faster Transplantation Be Life-Saving for Patients with Advanced Disease? Acta Haematol 2016. Tanase A, Tomuleasa C, Marculescu A, Bardas A, Colita A, Orban C, Ciurea SO.
Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 2016. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO.
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biology of Blood and Marrow Transplantation 2016. Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, Kaur I, Fernandez-Vina M, Cao K, Ciurea S, Shpall EJ, Champlin RE.
Michael A. Caligiuri, M.D.
Zhijian “James” Chen, Ph.D.
Todd A. Fehniger, M.D., Ph.D.,
Helen Heslop, MD
Jeffrey S. Miller, M.D.